10times
18 Feb 2021Ended

Oligonucleotide ADC Design and Development An Emerging Field Building on the Success of ADCs in Cancer

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

Feb 2021

Frequency

Not Available
Claim event to edit details

Antibody-oligonucleotide conjugates (AOCs) are a growing sub-class of ADCs that utilize the oligonucleotide functionality in combination with the .. Read more antibody’s exquisite targeting ability and improved biodistribution profile. Oligonucleotides, as drug molecules, suffer from several drawbacks such as instability, impaired pharmacokinetics (PK), poor cellular uptake and sub-optimal tissue targeting. Tissue specific delivery of oligonucleotides can be facilitated via conjugation to a targeting moiety (e.g. As AOC therapeutic drug development grows there is a need to for robust, reproducible, and well-defined scale–up and manufacture processes to generate well characterised material for clinical trials. While the process development challenges of ADCs are focused on maximizing the loading of drug molecules to the antibody and minimizing the release of free payload, AOC development and manufacture has its own set of unique challenges. In this webinar, we will review oligonucleotide bioconjugates focusing upon their design, development, analysis and manufacture. Case studies which illustrate the chemical processes used in oligonucleotide conjugation and the analytics required to support development and manufacture will be presented.

  • Share your Experience
  • Organizer
Logo Follow Company

Xtalks

Canada416 Total Events / 57 Upcoming Events

More Events From The Organizer